[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 622,289,728
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.26
  • Price/Sales 6.51
  • Price/Cash Flow 18.04
  • Price/Book 7.55

Options Overview Details

View History
  • Implied Volatility 27.76% (-0.47%)
  • Historical Volatility 24.49%
  • IV Percentile 96%
  • IV Rank 87.81%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 2) 3.59 (1.41%)
  • Put/Call Vol Ratio 0.98
  • Today's Volume 14,656
  • Volume Avg (30-Day) 27,483
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 364,020
  • Open Int (30-Day) 362,465
  • Expected Range 250.38 to 257.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 7
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.84 +15.00%
on 06/01/26
259.90 -2.28%
on 06/30/26
+28.64 (+12.71%)
since 05/29/26
3-Month
220.37 +15.25%
on 05/11/26
259.90 -2.28%
on 06/30/26
+11.48 (+4.73%)
since 03/30/26
52-Week
152.81 +66.20%
on 07/01/25
259.90 -2.28%
on 06/30/26
+101.22 (+66.27%)
since 06/30/25

Most Recent Stories

More News
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END

HELP : 6.61 (-3.92%)
CMPS : 14.15 (-6.10%)
GHRS : 26.88 (-5.65%)
JNJ : 253.97 (-1.76%)
DFTX : 47.04 (+1.05%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients...

HELP : 6.61 (-3.92%)
CMPS : 14.15 (-6.10%)
GHRS : 26.88 (-5.65%)
JNJ : 253.97 (-1.76%)
DFTX : 47.04 (+1.05%)
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

GENEVA , June 26, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight...

JNJ : 253.97 (-1.76%)
Blackberry Stock Just Scored a New 'Buy' Rating. Here's Why.

Blackberry stock rallies as Stifel announces a bullish $12 price target. Here’s why the investment firm recommends owning BB shares at current levels.

BB : 12.65 (+1.36%)
NVDA : 200.09 (+2.63%)
QCOM : 184.79 (-2.08%)
JNJ : 253.97 (-1.76%)
AMD : 580.91 (+7.68%)
Johnson & Johnson Earnings Preview: What to Expect

Johnson & Johnson is scheduled to report its second-quarter results next month, and analysts expect a single-digit earnings rise.

XLV : 158.66 (-1.29%)
$SPX : 7,499.36 (+0.79%)
JNJ : 253.97 (-1.76%)
The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

APGE : 132.73 (+0.09%)
JNJ : 253.97 (-1.76%)
LLY : 1,199.43 (-2.48%)
ABBV : 251.64 (-1.05%)
REGN : 623.54 (-1.31%)
SNY : 42.66 (-1.77%)
3 Best ETFs to Kick Volatility to the Curb

Low- and minimum-volatility ETFs can help investors fade turbulence in the markets while still participating in upside.

SPLV : 74.90 (-0.91%)
VFMV : 139.36 (+0.07%)
KO : 81.27 (-1.67%)
JNJ : 253.97 (-1.76%)
CNQ : 39.50 (+0.48%)
LVHI : 40.59 (-0.31%)
RIO : 94.93 (+0.68%)
SHEL : 77.54 (+0.85%)
DUK : 126.58 (-1.36%)
FE : 47.54 (-1.08%)
How to Hunt for Mega-Cap Value After the SpaceX IPO

I'm not buying into SpaceX following the record-setting IPO. But I am looking for big value elsewhere. Here's how I start my search.

GOOG : 353.33 (+0.58%)
GOOGL : 357.37 (+1.05%)
SPCX : 170.86 (+4.06%)
$SPX : 7,499.36 (+0.79%)
BRK.A : 748,850.00 (+0.72%)
JPM : 327.33 (-0.63%)
BRK.B : 500.39 (+0.89%)
JNJ : 253.97 (-1.76%)
TOPT : 32.92 (+1.26%)
$IUXX : 30,276.35 (+1.68%)
AMZN : 238.34 (-0.75%)
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

HUM : 397.22 (+2.14%)
JNJ : 253.97 (-1.76%)
LLY : 1,199.43 (-2.48%)
DXCM : 67.35 (-3.76%)
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience,...

JNJ : 253.97 (-1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 264.92
2nd Resistance Point 262.41
1st Resistance Point 258.19
Last Price 253.97
1st Support Level 251.46
2nd Support Level 248.95
3rd Support Level 244.73

See More

52-Week High 259.90
Last Price 253.97
Fibonacci 61.8% 218.99
Fibonacci 50% 206.35
Fibonacci 38.2% 193.72
52-Week Low 152.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.